I agree with this, and his latest PR, while weak, does indicate the HIV strong treatment will be on the breaking market soon. That is according to the original schedule.
The audit needs releasing, even for just an impatient resolve. CC's always expressed a care for the shareholder, time to put up or shut up forever.
I also think the risks are coming to a very good benefit, and I will be accumulating more again myself, shoring up options on what I want to do.
He's also ignoring the worries of the political climate still being leveraged against Monoclonal antibody treatment producers, and I still think big US Pharma has a card to play in preventing small companies from running across the US markets with a cure.
And I don't give a rat's @$$ about the pink oval warning flashing on my screen above, for posting that obvious piece of relevant truth either.
News 
Market Data 
Discover 
AI
